Nephrotoxic Risk Associated With Combination Therapy of Vancomycin and Piperacillin-Tazobactam in Critically Ill Patients With Chronic Kidney Disease

被引:0
|
作者
Pipkin, Tamyah [1 ,7 ]
Pope, Stuart [2 ,8 ]
Killian, Alley [1 ]
Green, Sarah [1 ]
Albrecht, Benjamin [1 ]
Nugent, Katherine [3 ,4 ,5 ,6 ]
机构
[1] Emory Univ Hosp, Dept Pharm, Atlanta, GA USA
[2] Emory Univ Hosp Midtown, Dept Pharm, Atlanta, GA USA
[3] Emory Univ, Dept Med, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA USA
[6] Emory Univ, Div Crit Care Med, Sch Med, Atlanta, GA USA
[7] Norton Womens & Childrens Hosp, Dept Pharm, 4001 Dutchmans Ln, Louisville, KY 40207 USA
[8] Emory Univ Hosp Midtown, Dept Pharm, 550 Peachtree St NE, Atlanta, GA 30308 USA
关键词
acute kidney injury; vancomycin; piperacillin-tazobactam; chronic kidney disease; nephrotoxicity; INJURY;
D O I
10.1177/08850666241234577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The combination of vancomycin and piperacillin-tazobactam (VPT) has been associated with acute kidney injury (AKI) in hospitalized patients when compared to similar combinations. Additional studies examining this nephrotoxic risk in critically ill patients have not consistently demonstrated the aforementioned association. Furthermore, patients with baseline renal dysfunction have been excluded from almost all of these studies, creating a need to examine the risk in this patient population. Methods: This was a retrospective cohort analysis of critically ill adults with baseline chronic kidney disease (CKD) who received vancomycin plus an anti-pseudomonal beta-lactam at Emory University Hospital. The primary outcome was incidence of AKI. Secondary outcomes included stage of AKI, time to development of AKI, time to return to baseline renal function, new requirement for renal replacement therapy, intensive care unit and hospital length of stay, and in-hospital mortality. Results: A total of 109 patients were included. There was no difference observed in the primary outcome between the VPT (50%) and comparator (58%) group (P = .4), stage 2 or 3 AKI (15.9% vs 6%; P = .98), time to AKI development (1.7 vs 2 days; P = .5), time to return to baseline renal function (4 vs 3 days; P = .2), new requirement for RRT (4.5% vs 1.5%; P = .3), ICU length of stay (7.3 vs 7.4 days; P = .9), hospital length of stay (19.3 vs 20.1 days; P = .87), or in-hospital mortality (15.9% vs 10.8%; P = .4). A significant difference was observed in the duration of antibiotic exposure (3.32 vs 2.62 days; P = .045 days). Conclusion: VPT was not associated with an increased risk of AKI or adverse renal outcomes. Our findings suggest that the use of this antibiotic combination should not be avoided in this patient population. More robust prospective studies are warranted to confirm these findings.
引用
收藏
页码:860 / 865
页数:6
相关论文
共 50 条
  • [1] The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime
    Molina, Kyle C.
    Barletta, Jeffrey F.
    Hall, Scott T.
    Yazdani, Cyrus
    Huang, Vanthida
    JOURNAL OF INTENSIVE CARE MEDICINE, 2020, 35 (12) : 1434 - 1438
  • [2] Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime
    Rutter, W. Cliff
    Cox, Jessica N.
    Martin, Craig A.
    Burgess, Donna R.
    Burgess, David S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (02)
  • [3] Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill Reply
    Schreier, Diana J.
    Rule, Andrew D.
    Barreto, Erin F.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) : 1521 - 1521
  • [4] Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem
    Blevins, Adam M.
    Lashinsky, Jennifer N.
    McCammon, Craig
    Kollef, Marin
    Micek, Scott
    Juang, Paul
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [5] Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study
    O'Callaghan, Kevin
    Hay, Karen
    Lavana, Jayshree
    McNamara, John F.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
  • [6] Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis
    Giuliano, Christopher A.
    Patel, Chandni R.
    Kale-Pradhan, Pramodini B.
    PHARMACOTHERAPY, 2016, 36 (12): : 1217 - 1228
  • [7] Acute kidney injury associated with piperacillin-tazobactam versus other antibiotics combined with vancomycin in critically ill patients: A retrospective cohort study
    Almutairi, Masaad S.
    Alnezary, Faris S.
    Chestnutt, Josh
    Mcallister, Matthew
    Almohammed, Omar A.
    Alhifany, Abdullah A.
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (12)
  • [8] Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime
    Navalkele, Bhagyashri
    Pogue, Jason M.
    Karino, Shigehiko
    Nishan, Bakht
    Salim, Madiha
    Solanki, Shantanu
    Pervaiz, Amina
    Tashtoush, Nader
    Shaikh, Hamadullah
    Koppula, Sunitha
    Koons, Jonathan
    Hussain, Tanveer
    Perry, William
    Evans, Richard
    Martin, Emily T.
    Mynatt, Ryan P.
    Murray, Kyle P.
    Rybak, Michael J.
    Kaye, Keith S.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (02) : 116 - 123
  • [9] Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem
    Rungkitwattanakul, Dhakrit
    Ives, Amy L.
    Harriott, Nicole G.
    Pan-Chen, Sarah
    Lan Duong
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (02) : 103 - 109
  • [10] Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study
    Hammond, Drayton A.
    Smith, Melanie N.
    Painter, Jacob T.
    Meena, Nikhil K.
    Lusardi, Katherine
    PHARMACOTHERAPY, 2016, 36 (05): : 463 - 471